➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Express Scripts
Harvard Business School
Mallinckrodt
McKinsey

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

DIABETA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Diabeta, and when can generic versions of Diabeta launch?

Diabeta is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in DIABETA is glyburide. There are twenty drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the glyburide profile page.

US ANDA Litigation and Generic Entry Outlook for Diabeta

A generic version of DIABETA was approved as glyburide by TEVA on August 29th, 1995.

  Start Trial

Drug patent expirations by year for DIABETA
Drug Sales Revenue Trends for DIABETA

See drug sales revenues for DIABETA

Recent Clinical Trials for DIABETA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NovartisPhase 2
TakedaPhase 4
TakedaPhase 3

See all DIABETA clinical trials

US Patents and Regulatory Information for DIABETA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-001 May 1, 1984 AB2 RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-002 May 1, 1984 AB2 RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-003 May 1, 1984 AB2 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIABETA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-003 May 1, 1984   Start Trial   Start Trial
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-003 May 1, 1984   Start Trial   Start Trial
Sanofi Aventis Us DIABETA glyburide TABLET;ORAL 017532-002 May 1, 1984   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Harvard Business School
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.